Latest Breaking News On - Fibrotic liver disease consortium investigators - Page 1 : vimarsana.com

Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement

Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomHong kongIpsen euronextClin gastroenterol hepatolCarol robertsChristelle huguetAnna gibbinsIpsen iqirvoRachel reiffKris kowdleyNicolas boglerAmy wolfLiver instituteIpsen pharmaceuticals inc

Ipsen Pharma: Ipsen s Iqirvo® receives U S FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

France generalUnited statesUnited kingdomHong kongChristelle huguetRachel reiffKris kowdleyNicolas boglerAnna gibbinsAmy wolfCarol robertsClin gastroenterol hepatolIpsen euronextIpsen pharmaceuticals incRegulatory agencyLiver institute

Ipsen s Iqirvo® receives U S FDA accelerated approval as a

Ipsen s Iqirvo® receives U S FDA accelerated approval as a
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesHong kongUnited kingdomCarol robertsAnna gibbinsRachel reiffIpsen euronextClin gastroenterol hepatolNicolas boglerAmy wolfChristelle huguetKris kowdleyEuropean medicines agencyIpsen pharmaceuticals incFibrotic liver disease consortium investigators